伴同性動物藥物市場規模、佔有率和成長分析（按伴同性動物、藥物類別、分銷管道和地區）- 產業預測 2025-2032

伴同性動物藥物市場規模預計將在 2023 年達到 158 億美元，從 2024 年的 168.7 億美元成長到 2032 年的 285.6 億美元，在預測期內（2025-2032 年）的複合年成長率為 6.8%。

受寵物擁有量激增、寵物保健意識增強和動物用藥品進步的推動，全球伴同性動物藥物市場正在蓬勃發展。隨著越來越多的家庭飼養寵物，對狗、貓和其他動物的藥物和治療的需求不斷成長。主要成長動力包括更重視預防性醫療保健，包括接種疫苗和驅蟲，以及多樣化的慢性病治療方案。此外，藥物傳輸系統的創新，例如調味錠劑和外用製劑，正在改善飼主的藥物管理。隨著寵物健康成為首要任務，市場區隔將持續成長，為製藥公司和獸醫進入這個不斷擴大的市場提供了寶貴的機會。

目錄

介紹

• 調查目的
• 研究範圍
• 定義

調查方法

• 資訊採購
• 次要和主要資料方法
• 市場規模預測
• 市場假設與限制

執行摘要

• 全球市場展望
• 供需趨勢分析
• 細分機會分析

市場動態及展望

• 市場概況
• 市場規模
• 市場動態
  • 促進因素和機會
  • 限制與挑戰
• 波特的分析

主要市場考察

• 關鍵成功因素
• 競爭程度
• 主要投資機會
• 市場生態系統
• 市場吸引力指數（2024 年）
• PESTEL 分析
• 總體經濟指標
• 價值鏈分析
• 定價分析
• 監管分析
• 專利分析

伴同性動物藥物市場規模（以伴同性動物分類）

• 市場概況
• 狗
• 貓
• 馬
• 其他

伴同性動物藥物市場規模（依藥物類別分類）

• 市場概況
• 抗生素
• 消炎（藥
• 心絲蟲藥
• 殺寄生蟲劑
• 營養藥物
• 行為藥物
• 疫苗
• 其他

伴同性動物藥物市場規模（依分銷管道分類）

• 市場概況
• 獸醫藥房
• 電子商務
• 零售藥局

伴同性動物藥物市場規模

• 北美洲
  • 美國
  • 加拿大
• 歐洲
  • 德國
  • 西班牙
  • 法國
  • 英國
  • 義大利
  • 其他歐洲國家地區
• 亞太地區
  • 中國
  • 印度
  • 日本
  • 韓國
  • 其他亞太地區
• 拉丁美洲
  • 巴西
  • 其他拉丁美洲國家
• 中東和非洲
  • 海灣合作理事會國家
  • 南非
  • 其他中東和非洲地區

競爭資訊

• 前 5 家公司對比
• 主要企業市場定位（2024年）
• 主要市場參與者所採用的策略
• 近期市場趨勢
• 公司市場佔有率分析（2024 年）
• 主要企業簡介
  • 公司詳細資訊
  • 產品系列分析
  • 公司分部佔有率分析
  • 收益與前一年同期比較對比（2022-2024 年）

主要企業簡介

• Zoetis（USA）
• Elanco Animal Health（USA）
• Virbac（France）
• Ceva Sante Animale（France）
• Boehringer Ingelheim（Germany）
• Merck Animal Health（USA）
• Bayer Animal Health（Germany）
• Kemin Industries（USA）
• Hester Biosciences（India）
• Vetoquinol（France）
• Dechra Pharmaceuticals（UK）
• IDEXX Laboratories（USA）
• Mars Petcare（USA）
• Nestle Purina Petcare（Switzerland）
• Hill's Pet Nutrition（USA）
• Boehringer Ingelheim Vetmedica（Germany）
• MSD Animal Health（USA）
• Bayer HealthCare Animal Health（Germany）
• Virbac Animal Health（France）
• Ceva Animal Health（France）

結論和建議

Companion Animal Drugs Market size was valued at USD 15.8 billion in 2023 and is poised to grow from USD 16.87 billion in 2024 to USD 28.56 billion by 2032, growing at a CAGR of 6.8% during the forecast period (2025-2032).

The global companion animal drugs market is thriving, fueled by the surge in pet ownership, increased awareness of pet healthcare, and advancements in veterinary pharmaceuticals. As more households adopt pets, the demand for medications and treatments for dogs, cats, and other animals continues to rise. Key growth drivers include a heightened emphasis on preventive care-encompassing vaccinations and parasite control-and a diverse range of therapeutic solutions for chronic conditions. Furthermore, innovation in drug formulations and delivery systems, such as flavored tablets and topical applications, has improved medication administration for pet owners. With the ongoing prioritization of pet well-being, the companion animal drugs market is poised for sustained growth, presenting valuable opportunities for pharmaceutical companies and veterinarians to engage this expanding segment.

Top-down and bottom-up approaches were used to estimate and validate the size of the Companion Animal Drugs market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Companion Animal Drugs Market Segments Analysis

Global Companion Animal Drugs Market is segmented by Companion Animals, Drug Class, Distribution Channel and region. Based on Companion Animals, the market is segmented into Dogs, Cats, Horses and Others. Based on Drug Class, the market is segmented into Antibiotics, Anti-inflammatory, Heart Worm Drugs,parasiticides, Nutritional Drugs, Behavioral Drugs, Vaccines and Others. Based on Distribution Channel, the market is segmented into Veterinary Pharmacies, E-commerce and Retail Pharmacies. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Companion Animal Drugs Market

The Companion Animal Drugs market is experiencing significant growth driven by advancements in veterinary medicine. These enhancements encompass the creation of more effective diagnostics, treatments, and pharmaceuticals. As a result, the variety of treatment options available is expanding, leading to improved disease management and higher efficacy in therapy. This progress has heightened the demand for advanced medications for companion animals, reflecting a growing recognition of the importance of pet health and well-being. Consequently, the overall landscape of the companion animal drug market is evolving, creating opportunities for innovative solutions to address the medical needs of pets.

Restraints in the Companion Animal Drugs Market

The Companion Animal Drugs market is encountering significant challenges due to the financial strain associated with these medications and treatments. Many consumers are hesitant to invest in their pets' health because of the high costs involved, which can delay or obstruct market adoption. Pet owners, particularly those in low-income areas or with limited budgets, often perceive the prices of these healthcare options as prohibitively expensive. This can deter them from seeking necessary treatments and medications for their pets, ultimately impacting the growth and accessibility of the market for companion animal healthcare solutions.

Market Trends of the Companion Animal Drugs Market

The Companion Animal Drugs market is experiencing a significant trend towards digital health solutions, driven by the integration of advanced data analytics, telehealth services, wearable devices, and mobile applications. This technological shift enables pet owners to remotely monitor their animals' health indicators, fostering better communication with veterinarians and enhancing overall healthcare management. With these innovations, pet owners can efficiently manage medicinal prescriptions and adhere to treatment protocols, ultimately improving pet welfare and satisfaction. As the market continues to embrace these digital solutions, the demand for companion animal drugs is likely to increase, reflecting a broader trend towards personalized and proactive veterinary care.

Table of Contents

Introduction

• Objectives of the Study
• Scope of the Report
• Definitions

Research Methodology

• Information Procurement
• Secondary & Primary Data Methods
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Global Market Outlook
• Supply & Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Overview
• Market Size
• Market Dynamics
  • Drivers & Opportunities
  • Restraints & Challenges
• Porters Analysis
  • Competitive rivalry
  • Threat of substitute
  • Bargaining power of buyers
  • Threat of new entrants
  • Bargaining power of suppliers

Key Market Insights

• Key Success Factors
• Degree of Competition
• Top Investment Pockets
• Market Ecosystem
• Market Attractiveness Index, 2024
• PESTEL Analysis
• Macro-Economic Indicators
• Value Chain Analysis
• Pricing Analysis
• Regulatory Analysis
• Patent Analysis

Global Companion Animal Drugs Market Size by Companion Animals & CAGR (2025-2032)

• Market Overview
• Dogs
• Cats
• Horses
• Others

Global Companion Animal Drugs Market Size by Drug Class & CAGR (2025-2032)

• Market Overview
• Antibiotics
• Anti-inflammatory
• Heart Worm Drugs
• Parasiticides
• Nutritional Drugs
• Behavioral Drugs
• Vaccines
• Others

Global Companion Animal Drugs Market Size by Distribution Channel & CAGR (2025-2032)

• Market Overview
• Veterinary Pharmacies
• E-commerce
• Retail Pharmacies

Global Companion Animal Drugs Market Size & CAGR (2025-2032)

• North America (Companion Animals, Drug Class, Distribution Channel)
  • US
  • Canada
• Europe (Companion Animals, Drug Class, Distribution Channel)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Companion Animals, Drug Class, Distribution Channel)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Companion Animals, Drug Class, Distribution Channel)
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Companion Animals, Drug Class, Distribution Channel)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2024
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2024
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2022-2024)

Key Company Profiles

• Zoetis (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Elanco Animal Health (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Virbac (France)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Ceva Sante Animale (France)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Boehringer Ingelheim (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Merck Animal Health (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bayer Animal Health (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Kemin Industries (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Hester Biosciences (India)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Vetoquinol (France)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Dechra Pharmaceuticals (UK)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• IDEXX Laboratories (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Mars Petcare (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Nestle Purina Petcare (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Hill's Pet Nutrition (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Boehringer Ingelheim Vetmedica (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• MSD Animal Health (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bayer HealthCare Animal Health (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Virbac Animal Health (France)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Ceva Animal Health (France)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations